Elliott J, Kelly SE, Bai Z, et al. - Via this umbrella review of systematic reviews of randomized controlled trials, researchers intended to define the optimal length of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention with stenting. They assessed death, myocardial infarction (MI), stroke, stent thrombosis, major adverse cardiac and cerebrovascular events, bleeding, and urgent revascularization in relation to an extended DAPT (> 12 months) vs DAPT for 6 to 12 months post-percutaneous coronary intervention with stenting. Among clinically significant subgroups (eg, elderly patients, those with diabetes, prior MI, acute coronary syndrome), they looked at the evidence of advantages and harms. As per the findings, the risk of MI and stent thrombosis may be reduced by extended DAPT, but this strategy increased the risk of major bleeding and death. It remained unclear if the impacts of extended DAPT were consistent across patient subgroups.